HistoGeneX Revenue and Competitors

Barton, AU

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • HistoGeneX's estimated annual revenue is currently $99.8M per year.(i)
  • HistoGeneX's estimated revenue per employee is $155,000

Employee Data

  • HistoGeneX has 644 Employees.(i)
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$95.5M616-23%N/AN/A
#2
$34.7M224N/AN/AN/A
#3
$15.5M1006%N/AN/A
#4
$13.8M895%N/AN/A
#5
$15.8M1022%N/AN/A
#6
$21.5M1399%N/AN/A
#7
$20.3M131-26%N/AN/A
#8
$10.4M67-29%N/AN/A
#9
$9.7M84-14%$412.3MN/A
#10
$23.7M153-10%N/AN/A
Add Company

At HistoGeneX, we take pride in bridging technologies, expertise, and experience. Connect with us on Twitter @HistoGeneX or visit HistoGeneX Laboratories on Youtube. HistoGeneX Laboratories is a privately held service provider of biomarker technologies for translational and clinical research and is a CAP, CLIA and BELAC-accredited laboratory. With facilities located in Antwerp, Belgium and Chicago, Illinois, and taking steps to establish a site in China, HistoGeneX provides a networked footprint for global clinical trials. Our services and products stem from a pathology and patient care perspective. We are experts at handling all human biological specimens and deploy the relevant technologies to extract the valuable information contained within for research and diagnostic applications. We provide assay development and testing services to support a wide variety of translational medicine, clinical trials, and in vitro diagnostic applications. Our laboratory combines innovative technologies to interrogate DNA, RNA and proteins to categorize, enumerate and understand cancer. Our leadership comes from various aspects of diagnostic and therapeutic backgrounds. HistoGeneX leads the biomarker immune-oncology field. We have devoted attention to developing innovations in assessing the immune system within the tumor microenvironment. Our key advances include: · A strong portfolio of immuno-oncology related biomarkers. · A large number of immuno-oncology trials across multiple tumor types. · Experience with semi-quantitative and quantitative imaging. · Experience with IVD assays and diagnostic companies. · Self-Investment in immuno-oncology research. Oncology, Tissue Analysis, Molecular Techniques, Tumor Profiling, Personalized Medicine, Biotechnology

keywords:N/A

N/A

Total Funding

644

Number of Employees

$99.8M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35M677-6%N/A
#2
$35M6899%N/A
#3
$403.7M10689%N/A
#4
$75M1101-1%N/A
#5
$35M1136N/AN/A